Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Stock Declines Leave Novartis, P&G With More Options

Executive Summary

Novartis is riding high expectations for the COX-2 inhibitor Prexige to a new level of prestige on Wall Street
Advertisement

Related Content

Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street
Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street
Bear Stearns Healthcare Conference In Brief
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Wholesaler Interest: Rates Make Forward Buys Pay; Do Generics Pay Better?
Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs
Advertisement
UsernamePublicRestriction

Register

PS040164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel